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Abstract
Background: DNA sequence diversity within the human genome may be more greatly affected by copy
number variations (CNVs) than single nucleotide polymorphisms (SNPs). Although the importance of
CNVs in genome wide association studies (GWAS) is becoming widely accepted, the optimal methods for
identifying these variants are still under evaluation. We have previously reported a comprehensive view of
CNVs in the HapMap DNA collection using high density 500 K EA (Early Access) SNP genotyping arrays
which revealed greater than 1,000 CNVs ranging in size from 1 kb to over 3 Mb. Although the arrays used
most commonly for GWAS predominantly interrogate SNPs, CNV identification and detection does not
necessarily require the use of DNA probes centered on polymorphic nucleotides and may even be
hindered by the dependence on a successful SNP genotyping assay.
Results: In this study, we have designed and evaluated a high density array predicated on the use of non-
polymorphic oligonucleotide probes for CNV detection. This approach effectively uncouples copy number
detection from SNP genotyping and thus has the potential to significantly improve probe coverage for
genome-wide CNV identification. This array, in conjunction with PCR-based, complexity-reduced DNA
target, queries over 1.3 M independent NspI restriction enzyme fragments in the 200 bp to 1100 bp size
range, which is a several fold increase in marker density as compared to the 500 K EA array. In addition,
a novel algorithm was developed and validated to extract CNV regions and boundaries.
Conclusion: Using a well-characterized pair of DNA samples, close to 200 CNVs were identified, of
which nearly 50% appear novel yet were independently validated using quantitative PCR. The results
indicate that non-polymorphic probes provide a robust approach for CNV identification, and the
increasing precision of CNV boundary delineation should allow a more complete analysis of their genomic
organization.
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Background
With the completion of the human genome sequence, it is
generally accepted that any two individuals are ~99.9%
identical at the nucleotide level, and that the presence of
single nucleotide polymorphisms (SNPs) in the genome
are the major contributor to genetic diversity among
humans [1]. In part due to the accuracy and ease in which
they can be scored, along with their stability and abun-
dance in the genome, SNPs have become the marker of
choice for whole genome association studies that use link-
age disequilibrium (LD) mapping to identify genes
involved in complex diseases [2,3]. Over the last several
decades, it has also been accepted that there can be DNA
copy number changes that occur among individuals,
albeit in the context of limited and specific loci within the
genome. These changes can span a spectrum from, for
example, an extra copy of an entire chromosome (trisomy
21) in Down's syndrome to sub-chromosomal deletions
responsible for genetic traits such as color blindness and
α and β thalassemias [4]. However, this paradigm of
genetic variation underwent a major revision in 2004 with
the identification of genome-wide copy number variants
that occur among phenotypically normal individuals
[5,6]. Since these initial reports, a large number of studies
have described the wide spread and global distribution of
CNVs in the genome [7-17]. As the cataloguing of CNVs
in the genome continues, new studies are also aimed at
understanding their function in normal cellular processes
such as drug metabolism [18,19] and gene expression
[20], in human disease susceptibility [21-23] and devel-
opmental disorders [24], and in the natural selection
process [25]. Lastly, the role of CNVs in genomic disorders
further underscores how profoundly gene function can be
adversely affected in a multitude of ways that can lead to
disease [26-29]. Recent estimates of the contribution of
CNVs to total nucleotide diversity per genome range from
9 to 30 Mb and thus exceeds the ~3 Mb estimated to be
due to SNPs [7,9,30]. In fact, a recent comparison of the
genome sequence of an individual human with the NCBI
human reference assembly suggested that DNA copy
number variable regions contribute ~10 Mb to sequence
heterogeneity [31]. These results underlie the growing
appreciation for and understanding of the need to
account for CNVs in genome wide association studies.
Although some common CNVs are in LD with SNPs and
can therefore be assayed indirectly through SNP genotyp-
ing, a significant fraction of CNVs (particularly those in
duplication-rich regions of the genome) are not well-cap-
tured by available SNP marker sets [7,12,14,32]. Further-
more, even taggable CNVs need to be accurately typed
before appropriate markers can be identified. Thus there is
still an on-going need to develop molecular methods
capable of direct and accurate detection of CNVs in order
for this new class of polymorphisms to be effectively
incorporated into genome wide LD mapping of genes
involved in human disease [33].
There is a wide range of structural variation that can occur
in the genome that includes deletions, insertions, duplica-
tions, and inversions, and these can range from 1–500 bp
(fine-scale), 500 bp–100 kb (intermediate-scale), and
>100 kb (large-scale) in size. Although there are many dif-
ferent molecular cytogenetic techniques that can be used
to assess variants when one or several specific targeted loci
are under investigation [26,34,35], there are only a lim-
ited number of approaches that provide genome-wide
characterization, namely direct sequencing approaches
such as fosmid paired-end sequencing [15] or Paired-End
Mapping (PEM) [30] and array-based methods. Array-
based methods that have been applied to CNV identifica-
tion include the use of BAC clones [5,7-9] and both long
[6,36] and short oligonucleotide probes [7,12,37]. We
have reported in 2006 on a comprehensive analysis of
CNVs in the HapMap DNA collection using two comple-
mentary platforms, namely BAC-array CGH and 500 K EA
high-density genotyping array. While these two
approaches often identified the same CNVs, there were
differences in the types of CNVs unique to each approach.
For example, while the 500 K EA array tended to identify
smaller CNVs along with higher border resolution, the
BAC array CGH approach was able to interrogate regions
of the genome that are not easily amenable to SNP geno-
typing due to the presence of low copy repeat structures
(segmental duplications). As a means to uncouple the
requirement of SNP genotypes from CNV identification,
we have designed and evaluated an array that uses non-
polymorphic 25-mer probes in combination with a PCR-
based, reduced complexity DNA target. This array has
been used for high resolution analysis of DNA deletions
in Gorlin syndrome samples [38], and in this report we
show using a well-characterized pair of DNA samples, in
conjunction with a novel CNV detection algorithm, that
nearly 200 CNVs are identified, of which over 120 had not
previously been described in this specific sample pair. All
novel CNVs were evaluated using an independent QPCR
based method, and the overall results show a verification
rate of nearly 85%. Thus, DNA probes designed to sites in
the genome that do not contain SNPs are effective for
CNV identification, and when combined with probes
used for SNP genotyping, provide a potentially powerful
approach for the integration of CNVs and SNPs into
genome wide association studies.
Results
Whole genome sampling analysis (WGSA) uses single
primer PCR in combination with adapter-ligated, restric-
tion enzyme-digested genomic DNA as template to selec-
tively and reproducibly amplify genomic fractions [39].
Based on in silico NspI restriction enzyme digestion of theBMC Genetics 2008, 9:27 http://www.biomedcentral.com/1471-2156/9/27
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human reference genome (Build 35), over 1.33 million
independent fragments are predicted in the 200 bp to
1100 bp size range. The 500 K EA array, which was previ-
ously used for genome-wide CNV detection, uses both
NspI and StyI PCR representations on two individual
arrays. In this configuration, the NspI WGSA target inter-
rogates ~250 K SNPs which in general each reside on a
unique restriction fragment. Thus only ~20% (0.25 M/1.3
M) of the in silico predicted NspI fragments are estimated
to be represented on the 500 K EA array in the form of
probes querying SNPs. Since the NspI PCR target has an
estimated complexity of 550 Mb, it could potentially serve
as a means to interrogate a significant fraction of the
genome provided that two key criteria are met, namely,
that these sequences can be reliably amplified by PCR dur-
ing WGSA and that probes for all fragments are repre-
sented on the array and function in a specific manner in
DNA hybridization. To this end, a new array was designed
using non-polymorphic probes (referred to as the Nsp
copy number (CN) array) for the goal of CNV detection.
The Nsp CN array contains eight to ten independent, non-
polymorphic probes per restriction fragment which were
selected based on intrinsic criteria (see Methods). Glo-
bally, these arrays, in combination with NspI WGSA target
only, result in an increase in probe coverage when com-
pared to the 500 K EA genotyping arrays which used both
NspI and StyI WGSA fractions (Figure 1). The median
inter-marker distance for the Nsp CN arrays is 776 bp,
compared to 2709 bp for 500 K EA probes [37]. As
expected, genome coverage is improved. For example, at
an inter-marker distance of 2.5 Kb, the 500 K EA array cov-
ers ~46% of the genome whereas coverage increases to
over 84% with the Nsp CN array. Because the selection of
probe sequences is no longer constrained to SNPs, this
array design also has improved coverage in regions likely
to contain CNVs, such as segmental duplications [8]. For
example, while only 25.7% of segmental duplications
contain at least one SNP found on the 500 K EA array,
90.3% of segmental duplications are represented by
probes from at least one restriction fragment on the Nsp
CN array before probe filtering (Table 1).
Assay and array performance
Although the human reference genome is commonly used
to predict outcomes of in silico restriction enzyme diges-
tions, the precise relationship between all expected frag-
ments, regardless of whether they contain a SNP or not,
and the WGSA target output has not been systematically
evaluated [40,41]. The Nsp CN array, which contains mul-
tiple independent probes per fragment, was used to eval-
uate how well each fragment is represented by the WGSA
assay. For this purpose, the difference was estimated
between probe-specific background (using a pooled panel
of 'antigenomic' probes that are not present in the human
genome and which vary in GC content in a similar man-
ner to the perfect match probes [42]), and the target-
dependent probe signal using a set of five genomic DNA
samples that contain different numbers of X chromo-
somes (designated as the 1X to 5X sample set). Using a
probe sequence-specific background model (see Meth-
ods), >97% of all probes show an intensity that is higher
than background in each individual sample and > 94% of
all probes are detected above background when all 5 sam-
ples are evaluated together as a group (Table 2). Although
this metric does not measure the specificity of the signal
per se but rather whether the signal is real or not in terms
of being above background level, it does suggest that
nearly all predicted restriction fragments are actually rep-
resented in the PCR target at a concentration sufficient for
detection by hybridization. The small remaining set of
non-responsive fragments could result from problems
with restriction enzyme digestion, PCR amplification,
hybridization, or sequence differences between the
Table 1: Coverage of segmental duplication regions by 500 K EA and Nsp CN arrays.
500 K EA Nsp CN array
Before probe 
filtering
After probe 
filtering
After local-
correction 
filtering
After probe 
filtering
After local-
correction 
filtering
After probe 
filtering
After local-
correction 
filtering
Data set 1 Data set 2 Data set 3
At least one 
marker
25.7% 90.3% 74.1% 73.5% 74.3% 73.8% 74.0% 73.0%
At least two 
markers
13.4% 85.2% 61.7% 60.5% 61.8% 60.7% 61.6% 60.3%
At least three 
markers
7.7% 78.1% 50.4% 49.2% 50.7% 49.5% 50.2% 49.1%
At least four 
markers
5% 69.7% 40.7% 39.1% 41.0% 39.3% 40.7% 39.3%
Note: Each data set represents a replicate of 1X–5X samples. For 500 K EA, marker refers to SNPs; For Nsp CN array, markers refer to Nsp 
fragments.
Segmental duplication data source [80]BMC Genetics 2008, 9:27 http://www.biomedcentral.com/1471-2156/9/27
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human genome reference sequence and the genomes of
the samples being tested.
The probes present on the Nsp CN array have not been
experimentally selected a priori for high performance with
regard to detection of DNA copy number changes. In
order to test if these probes are sensitive to changes in tar-
get dosage, the 1X to 5X DNA samples were used in WGSA
and target was hybridized to the arrays for the purpose of
X chromosome probe evaluation. Using all probes present
on the X chromosome, a clear increase in signal was seen
with increasing X chromosome dosage (Additional File
1). These results confirm that probes on the Nsp CN array
display a dose response for the X chromosome. The use of
these DNA samples also allows assessment of individual
probe-specific dose response metrics (i.e. regression slope
and linear correlation coefficient). For example, under
ideal theoretical conditions, a single probe that maps to
only one site on the X chromosome, when evaluated with
the 1X to 5X sample set, would show a regression slope
value of 1 when the linear regression is modeled using the
log-transformed intensity as the response and the log-
transformed copy number as the predictor. Similarly, a
linear correlation coefficient of 1 would be expected.
Thus, deviation from these ideal values provides an exper-
imental approach to measuring each probe's ability to
respond to changes in target concentration. Two examples
are shown in Additional Files 2 and 3.
The impact of the number of genomic hits on probe dose
response was also evaluated using the X chromosome
probe intensities from the 1X–5X data set (Additional File
2). Linear correlation between log (probe intensity) and
log (chrX copy number) was calculated for each of the
chrX probes after grouping probes by number of perfect-
match genomic hits. The Pearson's correlation coefficient
of each group (Additional File 2B) dramatically decreased
when the number of genomic hits was greater than two.
The log (probe intensity) and log (chrX copy number) was
further modeled by simple linear regression. Again, the
regression coefficient (regression line slope, as shown in
Additional File 2C) grouped by number of genomic
Genome coverage of the Nsp CN array before and after probe filtering compared with 500 K EA arrays Figure 1
Genome coverage of the Nsp CN array before and after probe filtering compared with 500 K EA arrays. The X-
axis is the distance between any given point in the gap-adjusted genome and the next closest marker. The curve shows the 
proportion of the genome where the closest marker is less than a certain distance. For example, for the after probe filtering 
Nsp CN array markers, 99.0% of the genome is less than 10 kb away from a Nsp fragment marker (compared to 99.8% for the 
before probe filtering Nsp CN array markers) while for the 500 K EA selected SNPs, only 84.9% of the genome has a SNP 
within 10 kb.BMC Genetics 2008, 9:27 http://www.biomedcentral.com/1471-2156/9/27
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matches indicated poorer performance when the probes
were complementary to more than two sites in the
genome. The same analyses stratifying on the number of
chromosome X hits using the same set of chrX probes gave
similar results (Additional File 2D–2F). Although these
metrics were also smaller for probes with two-genomic
matches as compared to single-match probes, the magni-
tude of the reduction was not as large relative to the
change from two-genome matches to three or greater
genomic matches. More importantly, since many CNVs
are associated with segmental duplication regions, there is
an increased likelihood for probes in CNV regions to have
two genome hits. Thus, probes with two genome hits were
not omitted in order to allow interrogation of segmental
duplication regions (Table 1), while probes that have
more than two genomic hits were removed as described in
Methods.
Several probe filtering steps were implemented in addi-
tion to the probe filtering described above for genomic
hits in order to remove adversely performing probes (see
Methods). These additional procedures included filtering
based on probe GC content, restriction fragment length
and GC content, NspI restriction site characteristics,
hybridization signal intensities lower than background,
hybridization signals that are too bright, and probe sets
comprised of single probes. Following the probe filtering
steps, sequence specific standardization was performed
and the probes from each restriction fragment were sum-
marized as described in Methods. At the completion of all
filtering steps, ~77% of the initial probes and 92% of the
initial restriction fragments were retained in a typical
experiment, although the exact number varied dynami-
cally for each sample set that was analyzed together (Addi-
tional File 4). Importantly, genome coverage was not
significantly reduced by probe filtering (Figure 1)
although coverage in segmental duplication regions with
at least one marker was modestly reduced from 90% to
74% (Table 1). The overall impact of probe filtering as
well as a median polish procedure (Robust Multichip
Analysis (RMA)) on dose response was evaluated using
the 1X–5X sample set dose response metrics. The linear
correlation coefficient and the regression slope improved
significantly in both cases (Additional File 5).
Detection of copy number polymorphisms
To evaluate the capability of the Nsp CN array to identify
CNVs, multiple independent replicates of two well charac-
terized DNA samples (NA15510 as the test sample and
NA10851 as the reference sample) that contain known
copy number variations were used. Although CNVs in
these two samples have previously been identified using
Table 2: Estimation of number of probes that respond to target and display an intensity above the background
Probes above background in each sample Probes and fragments above background in 5/5 samples
Probe count Percentage Probes # (%) Fragment # (%)
data set 1
Sample1 12,017,471 97.47% 11,786,082 (95.59%) 1,329,822 (99.96%)
Sample2 12,025,953 97.54%
Sample3 12,075,266 97.94%
Sample4 12,092,454 98.08%
Sample5 12,080,046 97.97%
data set 2
Sample1 11,980,266 97.17% 11,697,525 (94.87%) 1,329,806 (99.96%)
Sample2 12,053,875 97.76%
Sample3 12,056,015 97.78%
Sample4 12,039,968 97.65%
Sample5 11,981,189 97.17%
data set 3
Sample1 11,965,896 97.05% 11,687,506 (94.79%) 1,329,818 (99.96%)
Sample2 12,061,150 97.82%
Sample3 12,027,025 97.54%
Sample4 12,060,619 97.82%
Sample5 12,040,767 97.66%
Note: Each data set represents a replicate of 1X–5X samples.BMC Genetics 2008, 9:27 http://www.biomedcentral.com/1471-2156/9/27
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high density oligonucleotide arrays [7,37], we hypothe-
sized that improved probe density in regions devoid of
SNPs, such as segmental duplications, should lead to the
discovery of additional variants. For this purpose, a novel
algorithm was developed to identify copy number varia-
tion regions. This algorithm contains three major parts as
depicted in Figure 2. Intensity pre-processing includes
probe filtering, standardization which takes into account
probe specific metrics known to influence hybridization
and signal intensity, and probe set summarization to pro-
vide a single measurement for each fragment. The genome
segmentation step initially removes outlier fragments,
uses kernel smoothing to improve the signal to noise
ratio, and then applies a regression tree based method to
divide the genome into consecutive regions. Lastly, CNV
region identification is achieved by a permutation based
test to define the significance threshold. The training set
data for tuning various algorithm parameters (see Meth-
ods) consisted of a single replicate of NA15510 compared
to NA10851. Tuned parameters were then used in subse-
quent analyses that included two independent test sets of
NA15510 versus NA10851 as well as several HapMap trio
samples.
Using the two independent test replicates between
NA15510 and NA10851, 195 high confidence CNVs were
identified in total (gains (98) and losses (97) were repre-
sented nearly equally), with 156 CNVs and 175 CNVs
found in each of the two pair-wise comparisons. This rep-
resents, on average, a five fold increase over the number of
CNVs identified in this same sample pair using 500 K EA
arrays [37]. In total, 10,126,153 nucleotides were
included in these CNV regions, representing 0.355% of
the gap-adjusted genome size, and 39.5% of the CNVs
overlapped with segmental duplications (Additional File
6A). The mean and median size of CNVs identified on the
Nsp CN array were significantly smaller as compared to
CNVs found on the 500 K EA arrays (51,930 bp and
20,780 bp versus 293,800 bp and 48,950 bp respectively),
a direct result of the improved probe coverage (Figure 3).
There were 121 CNVs identified in both sample sets, cor-
responding to a reproducibility rate of ~77% (Additional
File 6). There have been several reports describing CNVs
found in this specific pair of samples using multiple detec-
tion platforms such as fosmid paired-end sequencing,
whole genome tile path (WGTP) BAC array CGH, and 500
K EA arrays [7,15]. The overlap of the 195 CNVs with this
external data set identified 73 CNVs (37.44%) (Addi-
tional File 6), and thus these were considered to be vali-
dated based on the criteria of overlap with previously
described CNVs found in these two samples. Interestingly,
the average size of CNVs that overlapped with external
data was 91,536 bp as compared to an average size of
28,229 bp for those CNVs that did not overlap with exter-
Overview of the data analysis work flow (see Methods for details) Figure 2
Overview of the data analysis work flow (see Methods for details).
Preprocessing
Genome
Segmentation
Probe Filtering
Probe Standardization
Probe Set Summarization
Log Intensity calculation
Local Correction
Kernel Smoothing and
Regression Tree Partitioning 
CNV Identification
Determine Final CNV Regions
Permutation Test to Define 
CNV Significance Thresholds BMC Genetics 2008, 9:27 http://www.biomedcentral.com/1471-2156/9/27
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nal data. By virtue of no overlap with the external data
sets, there were 122 novel CNVs. 120 of these 122 CNVs
were tested by QPCR and the results showed that 94/120
(78.3%) could be validated (Additional File 6), indicating
that the majority of the novel CNVs represented real but
previously unidentified structural variation between
NA15510 and NA10851. Taken together, the percentage
of the 195 total CNV calls that were validated (based on a
combination of external data set overlap and QPCR anal-
ysis) was 86.5% and the percentage of CNV calls from
each pair-wise comparison that was validated was near
89% (Additional File 6). To assess the number of false-
positive CNV calls using this array and algorithm, 'self ver-
sus self' comparisons using the NA10851 reference sam-
ple were carried out. An average false discovery rate of
7.3% was determined (avg # CNV calls NA10851 vs
NA10851/avg # CNV calls NA10851 vs NA15510), which
is similar, although slightly lower, than the experimen-
tally identified rate of false positive calls of 11% (100%-
89%) for a test versus reference pair-wise sample compar-
ison.
Regions containing low copy repeats are often not detect-
able with SNP genotyping arrays since SNPs in these
regions do not typically perform well [43]. The Nsp CN
array contains non-polymorphic probes that are more
likely to span duplicated regions, and thus the power to
detect CNVs surrounding segmental duplications is
increased. From our union list of CNVs identified from
two replicates of NA15510 vs NA10851, we identified 77
CNVs (39.5%) that are associated with segmental duplica-
tions (Additional File 6), compared to 18 CNVs from a
similar data set using the 500 K EA array [7]. Figure 4 illus-
trates a CNV associated with a segmental duplication.
CNVs have previously been shown to be largely heritable
[7,8,14]. As such, the performance of the CNV detection
assay and algorithm was assessed by evaluating Mende-
lian inheritance (MI) of CNVs in two trios that are part of
the HapMap collection of DNA samples of Caucasian
(CEU) descent (Figure 5). The 6 samples that comprise the
two trio sets were each compared to the reference sample
(NA10851). Thus, all CNVs derived from these compari-
sons are a composite of copy number variation in the test
sample as well as the reference sample. This analysis
showed that 95.1% of CNVs (157/165) identified in the 2
children of these trios were also found in at least one of
the parents. This includes 113 CNVs that were called by
the algorithm in both the child and parent and are classi-
fied as inherited (Figure 5A) as well as 44 CNVs with sig-
nal intensities in one of the parents that were just below
the significance threshold cutoff and are classified as "dis-
Size distribution of CNVs detected using the Nsp CN array (red bars) compared with 500 K EA (blue bars) CNVs Figure 3
Size distribution of CNVs detected using the Nsp CN array (red bars) compared with 500 K EA (blue bars) 
CNVs.BMC Genetics 2008, 9:27 http://www.biomedcentral.com/1471-2156/9/27
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play MI trend" (Figure 5B, Additional File 6E). The
remaining CNVs could represent detection errors (false
positive CNVs in the child or false negative CNVs in either
parent), a "de novo" event in the child, a cell line artifact
in the child's sample [7], or an inherited CNV that has a
more complicated inheritance pattern (Figure 5C). To
evaluate these possibilities, all eight non-inherited CNVs
were evaluated for overlap with previously released data
sets that used the same samples [7,11,14,32] and were
also experimentally evaluated using QPCR (Additional
File 6D). This analysis showed that 4 of the 8 non-inher-
ited CNVs were truly present in the child's sample, but
were not detected in the parent's samples.
A comparison of the four validated "de novo" CNVs with
CNVs that have previously been described in the literature
for these samples reveals that one of these four can be cat-
egorized as a CNV with a complex inheritance pattern and
a second CNV can be categorized as a putative cell line
artifact. In the case of the trio which includes the child
DNA sample NA10846, a "de novo" CNV from
79,022,620 bp to 79,094,338 bp on chromosome 6 was
validated using several QPCR primer pairs targeting differ-
ent regions of the CNV (Figure 5C). In a previous study
[7], this common CNV region was identified as a deletion
in both parent samples (NA12144 and NA12145) as well
as the reference sample (NA10851), and was found to be
a homozygous deletion in the child (NA10846). Because
the reference sample and the two parents contain the
Improved ability to detect CNVs in segmental duplication regions Figure 4
Improved ability to detect CNVs in segmental duplication regions. In this CNV region associated with two segmental 
duplications, there is one SNP probe on the edge of the region (54347071 bp on chromosome 16, represented by the black 
dot) on the 500 K EA array, but multiple probes present on the Nsp CN array. The three panels represent three independent 
replicates (one training replicate (data set 2) and two test replicates (data set 1 and data set3)) of the test sample NA15510 and 
the reference sample NA10851 on the Nsp CN array. The log intensity ratios are plotted on the Y axis and the genomic loca-
tion on the X axis. The red horizontal line represents the CNV region identified by the Nsp CN array and algorithm, while the 
purple horizontal lines represent segmental duplication regions. The green arrows indicate location of primers used for QPCR 
verification (listed in Additional File 6).BMC Genetics 2008, 9:27 http://www.biomedcentral.com/1471-2156/9/27
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same CNV allele, the presence of the deletion in the par-
ents was masked in our study. Thus, this is an example
where an apparently "de novo" or non-inherited CNV
appears to follow simple Mendelian inheritance but is
missed due to the configurations of genotypes in the
tested samples relative to the reference sample. In another
example, for the case of the trio NA10831-NA12145-
NA12146, a "de novo" CNV was validated between
84,014,256 bp and 84,037,846 bp on chromosome 7, but
only in a specific lot number of the DNA sample corre-
sponding to the child (Additional File 6). In previous
work, this region was identified as a deletion in the child
sample (NA10831), but not in the parent samples
(NA12145 and NA12146) and was thus flagged as a
potential cell line artifact [7].
High resolution breakpoint determination for CNVs
For the Nsp CN array, the CNV border was defined as the
middle point between the outer most fragment present in
a region showing significance and the nearest fragment
located outside of the significant region. For this reason,
the reported border for a CNV region is an approximation
of the true border, which should lie somewhere between
these two points. The accuracy of the array and algorithm
to delineate CNV boundaries was evaluated by experi-
mental testing of 2 CNV regions that were identified by
both the Nsp CN array as well as the 500 K EA platform
(Additional File 6C). The first CNV tested was identified
as a 40 kb insertion on chromosome 2 by the Nsp CN
array and a 65 kb insertion by 500 K EA (Figure 6A).
QPCR primers were designed to the regions immediately
adjacent to the borders defined by the Nsp CN array, inter-
nal to the defined borders, and to regions that differed
between the two platforms. The results show that the bor-
CNV inheritance patterns in two family trios Figure 5
CNV inheritance patterns in two family trios. Although most CNVs are clearly inherited (Figure 5A) or displayed an 
intensity profile in one of the parents that is just below the threshold cutoff (Figure 5B), there are CNVs that appear to be de 
novo (Figure 5C). This could be due to complicated inheritance of a common CNV present in both parents and the reference, 
a false positive in the child, or a de novo event in the child. The log intensity ratios are plotted on the Y axis (the dots repre-
sent the log intensity ratio of each probe) and the genomic location on the X axis. Red horizontal lines represent CNVs identi-
fied in our study and the black horizontal line in Figure 5B represents the same region in the parent that was identified in the 
child sample as a CNV region. (A) Transmission of a CNV from a father (NA12144) to the child (NA10846). (B) Transmission 
of a CNV from a father (NA12155) to the child (NA10831). In this case, the intensity profile in this region in the father is just 
below the significance threshold and was not called as a CNV. However, this region displayed a strong trend as a CNV. (C) A 
deletion CNV identified in the child (NA10846) is not found in either of the parents (NA12144 and NA12145).
A C BBMC Genetics 2008, 9:27 http://www.biomedcentral.com/1471-2156/9/27
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ders defined by the Nsp CN array and algorithm were
highly accurate and limited only by the density of markers
in the region (Figure 6). A comparison of the borders
reported by the Nsp CN array and the borders reported by
the 500 K EA array with the experimental QPCR results
shows that the higher density of markers in the Nsp CN
array is beneficial in the identification of the true border
of a CNV region.
A second example was tested which was defined as a larger
CNV by the Nsp CN array (95 kb insertion on chromo-
some 17) compared to 500 K EA (23 kb insertion on chro-
mosome 17). The primary reason for the smaller size on
the 500 K EA platform was the lack of SNP probes in the
segmental duplications that are associated with this CNV
(Figure 6B). Again, the Nsp CN array borders were found
to be more accurate (Additional File 6). It should be noted
that although this CNV is clearly larger than 23 kb, the
precise borders were difficult to establish due to the pres-
Improved boundary delineation with Nsp CN arrays compared to 500 K EA Figure 6
Improved boundary delineation with Nsp CN arrays compared to 500 K EA. The CNV in these examples were 
identified by both the 500 K EA platform (black lines) as well as the Nsp CN array (red lines). The three panels represent three 
independent replicates of the test sample NA15510 and the reference sample NA10851 on the Nsp CN array (data set 1 and 
data set 3 are test data sets and data set 2 is used as training set). The blue lines represent the log intensity ratios, with the dots 
indicating the location of each probe from the Nsp CN array. Colored vertical lines indicate different primer pairs, with green 
indicating a confirmed copy number change, and red indicating no detectable copy number change. The black dots on the black 
horizontal line represent SNP markers tiled on the 500 K EA arrays. A) This CNV was identified as a 40 kb insertion using the 
Nsp CN array, and a 65 kb insertion using the 500 K EA arrays. The primer pairs, ordered from left to right on the figure, are 
named 1 to 19 in Additional File 6C. B) This CNV was identified as a 95 kb insertion using the Nsp CN array and a 23 kb inser-
tion using 500 K EA. In addition, the CNV is flanked by segmental duplications (purple lines). Primers 1 through 9 are num-
bered from left to right in Additional file 6C.
ABBMC Genetics 2008, 9:27 http://www.biomedcentral.com/1471-2156/9/27
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ence of segmental duplications within and flanking the
region (Figure 6B).
Discussion and Conclusion
The routine testing of CNVs during genome wide associa-
tion studies has been widely proposed yet has not been
fully realized to the same extent as SNP genotyping [44-
46]. This goal is hindered in part by the fact that accurate
and sensitive detection of CNVs that span varying num-
bers of nucleotides poses greater technical challenges than
the genotype determination of a bi-allelic single nucle-
otide polymorphism. In addition, although SNPs can reli-
ably be identified by many different molecular assays
which all result in a common output (homozygous or het-
erozygous genotype call), CNV outputs can vary widely
depending on the specific technical platform, calling algo-
rithm, and reference DNA sample that is used [47,48].
The ability to accurately assess common copy number var-
iation requires the development of novel high throughput
technologies as well as the algorithms to extract and proc-
ess the appropriate information. Here we describe a high
density oligonucleotide array designed specifically for the
interrogation of copy number changes without the neces-
sity to genotype SNPs. In addition, we have utilized a CNV
detection algorithm that takes advantage of well estab-
lished standardization methods [37,49,50] as well as the
use of tree partitioning to segment the genome and delin-
eate the CNV borders, a method that has been previously
described for the identification of copy number changes
using high density arrays [51] and is a powerful alternative
to other segmentation algorithms [52-55]. We have fur-
ther justified the use of a tree partitioning model coupled
with a permutation test by extensive experimental valida-
tion of the CNV calls as well as the precision of the borders
determined by the algorithm.
The single largest advantage of high density DNA oligonu-
cleotide arrays is the vast amount of genetic information
generated in a single experiment through the use of mil-
lions of independent probe sequences [56-58]. The
increased value of higher density is evident based on the
increased number of CNVs called in any pair wise com-
parison, and the ability to detect much smaller CNVs
compared to other array based platforms [7]. For example,
we identified 169 validated CNVs in one pair wise com-
parison (NA15510 vs NA10851) alone. This far outnum-
bers the list of CNVs discovered (using the same test and
reference sample) by at least 5 other microarray based
platforms (See Supplementary Table 1 in [59]) although
is still less than the 241 alterations discovered by fosmid
end sequencing of NA15510 [15]. Remarkably, in this one
sample alone, more than 500 distinct copy number varia-
tions have been identified, and half of these have been
experimentally validated. This underscores the point that
any two human genomes may differ by tens of Megbases
of DNA sequence due to structural variation alone.
One issue with CNV survey studies to date is the lack of
overlap between variants identified using different plat-
forms [59-61]. In addition, although the databases cata-
loguing all published CNV regions contain hundreds of
Mbs of DNA, it is still unclear if a large proportion of these
CNVs may in fact be false positives [59,62]. We have high
confidence in the CNVs reported here since all have been
experimentally validated or have been identified by mul-
tiple technological platforms.
The presence of non-polymorphic probes improves array
performance by allowing more probes to be utilized, even
in more complex regions of the genome, such as segmen-
tal duplication regions, which are often not accessible
through standard SNP genotyping. Future whole genome
association studies should utilize both SNPs and CN
probes to maximize the information and content. While
SNP detection has been widely used and tested, this is the
first report of a non-polymorphic set of probes that can be
evaluated for eventual inclusion onto an integrated array
containing both polymorphic and non-polymorphic
probes [47,61]. A subset of probes from the Nsp CN array
has been empirically selected for maximum responsive-
ness and has been incorporated into the SNP 6.0 array
[63]. This array is currently being used to assess structural
variation in large sample sets. Finally, the Nsp CN arrays
have been shown to be capable of detecting cancer caus-
ing aberrations with known pathological consequences
[64]. Thus, this type of array could also be used for array-
based karyotyping in lieu of more time consuming and
expensive cytogenetic methods [65].
Methods
Array Design
The Nsp CN array contains 12,339,139 oligonucleotide
probes tiled onto two arrays. Probes were selected to rep-
resent each of the 1,330,354 fragments between 200–
1100 bp predicted to arise after digestion of human
genomic DNA with the restriction enzyme NspI. All data
presented is based on the human reference genome build
35 (May 2004 build). For all chromosomes, 8–10 PM
(perfect match) probes were identified per fragment using
a probe selection algorithm previously developed for high
density 25-mer arrays [66]. Simple repeats and SNP
sequences were avoided.
For background estimation, a pooled set of "antigenomic"
probes were used which has been matched to each perfect
match feature based on its GC content and which are not
present elsewhere in the genome [42].BMC Genetics 2008, 9:27 http://www.biomedcentral.com/1471-2156/9/27
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Data Analysis
I. Preprocessing
1. Probe Filtering
In order to extract the highest quality data from the Nsp-
CN arrays, several filtering steps were implemented to
remove adversely performing probes.
Probe filtering based on probe GC content, fragment length and GC 
content, and NspI restriction site characteristics
Several previous studies have suggested that the restriction
fragment length and GC content as well as probe GC con-
tent have a strong effect on feature intensity [37,52,67].
Analysis of the relationship between Nsp-CN array probe
intensity and its associated probe and fragment character-
istics (data not shown) have led to the first set of filtering
criteria: probes with less than 30% or greater than 60%
GC content were removed as well as probes within restric-
tion fragments greater than 1000 bp in length, <25% GC
content, or > 60% GC content. In addition, probes resid-
ing in fragments in which the enzyme recognition site
contains a SNP [68] were also filtered out.
Probe filtering based on number of genome hits
The xMAN (extreme Mapping of OligoNucleotides) algo-
rithm was used to map all Nsp CN probes to the human
genome [69]. Probes with more than two genomic hits
were discarded due to reduced ability to respond to
changes in target dosage.
After the above two filtering steps, the number of probes
was reduced from 12,339,139 to 10,379,759 (84.12%),
and the number of fragments were reduced from
1,330,354 to 1,245,607 (93.6%). The remaining set of fil-
ters was applied independently for each data set.
Filtering of high-intensity probes
Exploratory data analysis discovered that probes with the
highest intensity on the arrays had very low dose response
(Additional File 3), in part due to cross hybridization with
multiple sites in the genome. For each set of samples
being analyzed together, probes that were consistently in
the top 10% intensity categories were filtered out.
Filtering of low-intensity probes: estimation of background effects
In order to identify probes that consistently failed to pro-
duce a signal above the background level, a sequence spe-
cific model was used to estimate the contribution of
systematic noise to the probe signal intensity. Although
overall probe GC content plays a crucial role in the esti-
mation of background, recent studies have pointed out
that position dependent sequence effects are also impor-
tant [70-72]. Motivated by the sequence-specific model,
the following multiple linear regression model was used
to describe the background effect on the Nsp CN arrays:
where
• Intensityi is the probe intensity of probe i;
• α is the intercept of the regression;
• j = 1,...,25, representing the position along the probe i;
• k represents the base at position j;
• Pi,k is the percentage of nucleotides A, C, G in the probe i;
• βk,l is the effect of nucleotide percentage (A, C, or G) in
the probe, for a fixed base nucleotide k, the effect is mod-
eled as a polynomial of degree 3;
• Iijk is an indicator function such that it is 1 when the jth
position is base k in probe i, and it is 0 otherwise;
• γk,l is the effect of base k in position j, the effect is mod-
eled as a polynomial of degree 3;
• m = 1,2,...,24, representing the di-nucleotide position
along the probe i;
• n is the set of di-nucleotide nearest neighbor composi-
tions such as 'AA', 'AC', 'GT' etc;
• Iimn is an indicator function such that it is 1 when the
mth position is di-nucleotide n in probe i, and it is 0 oth-
erwise;
• δn,l is the effect of di-nucleotide in position m, the effect
is modeled as a polynomial of degree 3;
• εi is the error-term.
Log intensities of all 33,886 anti-genomic probes were fit-
ted to estimate parameters using least squares. Each array
was fitted separately and a total of 64 parameters were
estimated for each array. These parameters were used to
calculate the background-adjusted intensities for all inter-
rogation probes on the array, and the value of zero was set
as the threshold to determine whether signal was greater
than background. For each set of samples being analyzed
together, probes that exhibited a consistent signal lower
than background were filtered out.
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Probe filtering based on number of probes within a fragment (probe 
set)
The last probe filtering step removed probes where only a
single probe remained for a given fragment (due to filter-
ing from previous steps). Thus, every fragment is repre-
sented by at least two probes that have passed all filtering
criteria.
2. Probe Standardization
Inspired by previous studies demonstrating that probe
intensities are affected by fragment length, fragment GC
content, probe GC content, nucleotide locations on the
probe, and recognition site sequence of restriction
enzyme, optical background adjusted probe intensities
were fitted to a multiple linear regression model [37,70-
72]. The AIC stepwise auto-selection procedure was used
to identify the best model. The starting model has a 10
degree polynomial for each variable. A cubic term was
used with most of the variables and the subset of selected
variables can be slightly different from sample to sample.
The following multiple linear regression model was used
to fit the data:
where
• adjusted PMi is the optical background adjusted probe
intensity of probe i; for each array, the minimum intensity
from all interrogation probes is first identified and this
number minus 1 is regarded as the optical background
intensity and it is subtracted from all probe intensities;
• α, j, i, k, Pi,k, βk,l, Iijk, γk,l, m, n, Iimn, δn,l, εi have the same
meaning as in formula (1);
• Fi,o is the percentage of nucleotide A, C, or G in the frag-
ment on which probe i resides;
• ηo,l is the effect of A, C, or G percentage in the fragment,
for a fixed base nucleotide o, the effect is modeled as a pol-
ynomial of degree 3;
• L is the length of the fragment which corresponds to
probe i;
• λi,l is the effect of fragment length, the effect is modeled
as a polynomial of degree 3;
• Iic is an indicator function such that it is 1 when the
nucleotide at the 3' restriction cutting site is C and it is 0
otherwise;
• ζi is the effect of nucleotide at the 3' restriction cutting
site for the fragment on which probe i resides;
There are total of 77 parameters in this model consisting
of 1 α, 9 β, 45 γ, 9 δ, 9 η, 3 λ and 1 ζ. 100,000 autosomal
probes were randomly selected from probes which were
kept after filtering steps for each array. Optical back-
ground adjusted intensities from these 100,000 probes
were used to fit the model to estimate the model parame-
ters for each array. Using these estimated parameters,
residual intensities for all probes were predicted and these
standardized intensities were used in subsequent steps.
3. Probe Set Summarization
After filtering and standardization, probes residing on the
same Nsp I restriction fragment (i.e. the probe set) were
summarized to a single value using RMA, a median polish
based method developed previously for RNA expression
studies to account for feature effects due to probe compo-
sition [73]. The effect of RMA was evaluated using the 1X–
5X DNA samples, where the linear correlation coefficient
and the regression slope improved significantly (Addi-
tional File 5).
Pair-wise CNV Detection
CNV detection was implemented on a pair-wise basis by
comparing a single test sample with a single reference
sample. In this study, we only concentrate on discovering
CNVs from autosomal chromosomes. Immuglobulin
genes (Ig) were removed from the analysis. These regions
include IgK at 2p11, IgL at 22q11, and IgH at 14q32[74].
II. Genome Segmentation
1. Calculating log of intensity ratio
After the RMA summarization step, each probe set is rep-
resented by one single value. Subsequently, log intensities
of the reference sample were subtracted from the test sam-
ple to obtain the log intensity ratio.
2. Local correction
A local correction step was used to remove outlier frag-
ments based on the premise that a typical CNV region
should span more than one NspI fragment, and neighbor-
ing fragments within a CNV should have a similar log
intensity ratio. First, all significant fragments from each
chromosome were identified as fragments whose log
intensity ratio is 3 times higher than the chromosome spe-
cific standard deviation of the log intensity ratio. A single
non-significant fragment located between two significant
fragments was ignored for subsequent analysis as long as
the significant fragments were in the same direction
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(either positive log intensity ratios or both negative log
intensity ratios). Furthermore, if the two significant frag-
ments were very close in distance (<1 kb), all non-signifi-
cant fragments located between them were removed. In
addition, a single significant point was removed if neigh-
boring points, defined as the nearest upstream or down-
stream fragment within 100 kb, or any fragment within 1
kb, did not show a log intensity ratio greater than 2 times
the standard deviation of log intensity ratios. For a typical
pair-wise comparison, 0.8%–0.9% of the fragments were
filtered out in this step.
3. Kernel smoothing and regression tree partitioning to identify CNV 
regions
To make array data more comparable across different data
sets, the local-corrected intensities were first scaled to a
mean of zero by subtracting the mean log intensity ratio
for all autosomal fragments. Next, to improve the signal
to noise of the adjusted log intensity ratio data, kernel
smoothing was applied with a Gaussain kernel and a 10
kb bandwidth. Finally, in order to identify putative CNV
regions, the smoothed log intensity ratios were fitted to a
regression tree model as described previously [51,75]. The
end result is the partitioning of the genome into consecu-
tive genomic regions. A single measurement is derived
from each region which is the mean log intensity ratio
based on all fragments that are within the region.
The optimal value for the threshold complexity parameter
(cp), was empirically determined using a test sample,
NA15510 and a reference sample, NA10851. This param-
eter controls the complexity of the partitioning of the
regression tree. We tested a range of cp values, from
0.0001 (used in our previous study [51]) to 0.001 in a step
of 0.0001. The two major metrics used to evaluate this
parameter were 1) how well the final CNV list overlapped
with validated/reported known CNV regions in sample
NA15510 [7,15], and 2) whether regions either known to
undergo somatic rearrangement (such as the Ig loci) or
harbor previously identified CNVs are split into several
smaller regions. This cp parameter was finally set to
0.0004, indicating that splits which do not increase the
overall R-squared value by 0.04% were not tested. In the
process of building the regression tree, the "minsplit"
parameter was set to 3. When a genomic region contains
3 or less fragments, the tree building procedure was
halted. In the tree-pruning phase of the algorithm, 10 fold
cross-validation and the 1-SE (standard deviation) rule
were used to decide the size and the complexity of the
final tree model [51,75].
III. CNV Identification
1. Permutation approach to define CNV significance thresholds
To determine significance thresholds for defining CNV
regions in pair-wise comparisons, we used a permutation
test after the local correction and mean ratio adjustment.
The physical locations of the fragments were randomly
permuted 500 times and the permuted data was subjected
to the same kernel smoothing and regression tree parti-
tioning procedures with the same algorithmic parameters
as described above. A unique threshold was defined for
each size group based on the false discovery rate (FDR).
Genome partitioning results from the permutation runs
were parsed into 19 size groups containing 2, 3, 4, 5, 6, 7,
8, 9, 10, 11–15, 16–20, 21–30, 31–40, 41–50, 51–60, 61–
70, 71–80, 81–90, and 91–100 fragments to get size spe-
cific null distributions of the log intensity ratios. A unique
threshold was defined for each size group based on the
false discovery rate (FDR) [76,77] with even partitioning
of the FDR among all the size groups. The following for-
mula was used to determine the significance threshold for
each size group:
where
• Iij is the index for retrieving the significance threshold for
size group i on array j of the Nsp-CN array set, j = 1,2;
• fdr is the pre-specified maximal false discovery rate for
the whole Nsp-CN array set;
• Ng is the total number of size groups;
• Na is the number of arrays in the array set, Na = 2 for Nsp
CN array set;
• Npij is the number of genomic regions in the size group
i, based on results summarized from all the permutation
runs of array j;
• Ncij is the number of genomic regions in the size group
i, based on results from tree partitioning of the test sam-
ple's genome on array j;
Once the Iij was computed, Iij + 1 was the index used to
retrieve significance thresholds for size group i on array j.
Thresholds for amplifications and deletions were com-
puted separately. Significant regions from the partitioned
test sample were identified using these log intensity ratio
thresholds. For putative CNV regions containing more
than 100 fragments, which were not considered directly in
the permutation test, we used the threshold derived from
the 91–100 fragment group and required the log intensity
ratio to be greater than 3 times the standard deviation of
raw, unsmoothed autosomal log intensity ratios.
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The optimal number of falsely-detected CNVs for our test
sample was identified as eight (after testing values
between 1 and 10) using the following criteria: 1) overlap
of generated CNV regions with reported CNVs in the liter-
ature and 2) consistency with QPCR validation. This
number corresponds to a FDR (False Detection Rate) of
~5% since there are ~160 CNVs detected in each pair-wise
comparison (8/160).
2. Additional criteria for determining the final CNV regions
To generate the final list of CNV regions, the following
additional steps were taken:
1) Only putative CNV regions with average log intensity
ratios greater than 4 times the standard deviation of kernel
smoothed, autosomal log intensity ratios were retained.
2) Adjacent significant regions were merged to form one
larger CNV region and the log intensity ratio of the newly
merged region was averaged.
3) Only CNVs containing more than one significant frag-
ment were retained. Significance was based on having a
raw log intensity ratio at least 3 times more significant
than the standard deviation of raw, un-smoothed auto-
somal log intensity ratios.
Target preparation and hybridization to arrays
DNA from cell lines was purchased from the Coriell Insti-
tute for Medical Research (Camden, NJ). The DNA sam-
ples containing different numbers of X chromosomes (1X
to 5X sample set) are NA10851, NA15510, NA04626,
NA01416 and NA06061. The sample used for much of the
parameter tuning and CNV identification was the test
sample, NA15510. Additional samples include two Hap-
Map trios (NA10831, NA12155, NA12156, NA10846,
NA12144, NA12145). In all cases a normal male reference
sample, NA10851, was used for comparison.
For target preparation of the DNA, we used the whole
genome sampling assay (WGSA) as described by the man-
ufacturer for the Nsp250K SNP genotyping array [63].
Briefly, 250 ng of DNA is digested with NspI, adapter-
ligated, and PCR amplified using a single primer homolo-
gous to the adapter. After purification, 90 ug of frag-
mented and labeled target is hybridized onto the array.
For data quality assessment, genotype calls were generated
from 250 SNPs using the DM (Dynamic Modeling) call-
ing algorithm with cutoff p-value 0.26 [78]. Any arrays
giving rise to a call rate of less than 85% were redone.
QPCR validation of CNV regions
Quantitative PCR using the ABI 7500 Sequence Detection
System was used to independently validate CNVs detected
by our algorithm as described previously [37]. At least
four replicate reactions for novel CNVs were run for each
primer pair and the comparative ∆∆CT method (User Bul-
letin #2; Applied Biosystems) was used to calculate the
fold change at each locus between the test and reference
samples. In addition, a t-test p-value based on the ∆Ct val-
ues was used to determine the statistical significance of
the result. The thresholds for determining whether an
amplicon was validated or not were set using results from
seven independent X chromosome amplicons that were
each analyzed using the 1X to 5X DNA samples (Addi-
tional File 7). The 1X, 3X, 4X and 5X DNA samples were
compared to the normal female 2X sample for each of the
seven amplicons for a total of 28 measurements (4 com-
parative measurements per amplicon × 7 amplicons). All
results that showed a fold change less than 0.8 or greater
than 1.25 as well as a p-value < 0.01 were considered to be
significant. Using these thresholds, there were 24 of the 28
comparisons that reached significance. Of the four meas-
urements that did not meet significance, one (Chr
X_Amplicon 2) is a known copy number variant between
NA15510 (2X sample) and NA18501 (1X sample) and
thus this did not pass the fold change threshold. The
remaining three measurements all passed the fold change
threshold but did not pass the p-value cut-off. For ambig-
uous results, the QPCR was repeated and often new
primer pairs were designed as shown in the Additional
File 6. Of the 96 QPCR-validated CNVs, 18 were tested
with a single amplicon and 76 were tested with at least
two independent amplicons. Also, for CNVs that failed
QPCR validation, 23 out of 25 were tested with two or
more amplicons. Any one primer pair displaying signifi-
cance was considered evidence of CNV validation. Some
novel CNVs reside in regions of segmental duplication
that preclude the identification of QPCR primer pairs that
generate a single unique amplicon. Thus independent val-
idation of these CNVs is technically challenging, leading
to possible false negative results.
Data Release
The raw data from this study are posted at the Gene
Expression Omnibus with accession number GSE9053
[79].
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Additional file 1
Dose response plots of a representative 1X–5X data set. Panels a-d show 
the scatter plots of standardized natural log intensity of the 1X, 3X, 4X, 
and 5X samples relative to the 2X sample. Here, standardization refers to 
the following data transformation: standardized intensity of chromosome 
X probe = (intensity of chromosome X probe-mean intensity of the auto-
somal probes)/standard deviation of the intensity of autosomal probes. Red 
dots represent randomly selected chromosome X probes and black dots rep-
resent randomly selected autosomal probes. The blues lines are the Y = X 
lines. Panel e shows the relationship between the natural log-transformed 
intensity and the natural log-transformed copy number. Natural log-
transformed mean intensity of all chromosome X probes from the 1X–5X 
samples are plotted on the Y-axis and natural log-transformed copy 
number are plotted on the X-axis. The blue line is the linear regression line 
using the natural log-transformed mean intensity as response and natural 
log-transformed copy number as predictors.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-9-27-S1.pdf]
Additional file 2
Dose response of probes deteriorates as the number of genomic hits 
increases. Panel a shows the frequency distribution of genomic matches for 
a set of 80,000 randomly selected chromosome X probes. Panels b-c are 
box-plots showing the distribution of linear correlation coefficient and 
regression slope grouped by the number of genomic hits of a set of 80000 
randomly selected chromosome X probes. Panel d shows chromosome X 
hits frequency distribution of the same set of randomly selected 80000 
chromosome X probes. Panels e-f are box-plots showing the distribution of 
linear correlation coefficient and regression slope grouped by the number 
of chromosome X hits of this set of 80,000 randomly selected chromosome 
X probes. Natural log-transformed normalized (as described in Methods) 
intensity of chromosome X probes of a representative set of 1X–5X samples 
and natural log-transformed copy number were used to calculate linear 
correlation coefficient and regression slope for each probe.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-9-27-S2.jpeg]
Additional file 3
A 2-dimensional histogram showing the distribution of regression slope 
along with the distribution of natural log-transformed intensity. Natural 
log-transformed normalized (as described in Methods) intensity of 
80,000 randomly selected chromosome X probes of a representative set of 
1X–5X samples and natural log-transformed copy number were used to 
calculate the regression slope. The black vertical line denotes the maxi-
mum log intensity ratio and the green vertical line denotes the top 8% log 
intensity, above which there are few probes with high regression slopes. 
The top 10% intensity is used as the cut-off threshold in the probe filtering 
process.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-9-27-S3.jpeg]
Additional file 4
Number of remaining probes and fragments following probe filtering for 
3 replicates of 1X–5X samples. The data indicates the number of probes 
and fragments that have been retained after probe filtering for 3 replicates 
of the 1X–5X DNA samples.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-9-27-S4.xls]
Additional file 5
Dose response of probes improves after probe filtering and RMA procedure. 
Natural log-transformed normalized (as described in Methods) intensity 
of 80,000 randomly selected chromosome X probes of a representative set 
of 1X–5X DNA samples and natural log-transformed copy number were 
used to calculate linear correlation coefficient and regression slope for all 
probes(blue bars), natural log-transformed normalized intensity of post-
filtering 64,035 of the 80,000 randomly selected chromosome X probes 
and natural log-transformed copy number were used to calculate linear 
correlation coefficient and regression slope for the filtered probes(grey 
bars), and natural log-transformed post-RMA chromosome X probe set 
intensity and natural log-transformed copy number were used to calculate 
linear correlation coefficient and regression slope for the fragments (red 
bars).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-9-27-S5.jpeg]
Additional file 6
List of QPCR data and CNV coordinates. Table A represents the coordi-
nates of CNVs in NA15510 vs. NA10851. Table B summarizes QPCR 
results for NA15510 vs. NA10851. Table C represents QPCR results for 
the CNV border analysis. Table D represents QPCR results for Mendelian 
inheritance (MI) errors. Table E lists counts of CNVs in HapMap trio 
samples NA10846-NA12144-NA12125 and NA10831-NA12155-
NA12156.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-9-27-S6.xls]
Additional file 7
Chromosome X QPCR Analysis. The data represents QPCR analysis of 
seven independent X chromosome amplicons that were each analyzed 
using the 1X to 5X DNA samples.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
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